产品
编 号：F740872
分子式：C8H5Cl3FNO
分子量：256.49
分子式：C8H5Cl3FNO
分子量：256.49
产品类型
规格
价格
是否有货
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 349106-80-5
产品详情
生物活性：
LDCA is a dual-hit metabolic modulator and inhibits LDH-A enzyme activity to stimulate apoptosis in the malignant population. LDCA can be used for the research of oncogenic progression.
体内研究：
LDCA (2 mg/kg, iv., the 6th day, once) is used in combination with doxorubicin thwarts tumor growth kinetics to restrain oncogenic progression, thus accentuating survival in the model of murine melanoma.Animal Model:melanoma tumor model
Dosage:2 mg/kg
Administration:2 mg/kg, iv., the 6th day, once
Result:Significantly increased mice survivability combination with doxorubicin, and relieved mice tumor necrosis phenomena.
体外研究：
LDCA (2-100 μM; 16-72 h) is used in combination with doxorubicin synergistically, enhances the growth inhibition and induces mitochondria-mediated apoptosis by recruiting the caspase cascade, restricting migration, and obviating the clonogenic outgrowth potential of melanoma cells.
LDCA is a dual-hit metabolic modulator and inhibits LDH-A enzyme activity to stimulate apoptosis in the malignant population. LDCA can be used for the research of oncogenic progression.
体内研究：
LDCA (2 mg/kg, iv., the 6th day, once) is used in combination with doxorubicin thwarts tumor growth kinetics to restrain oncogenic progression, thus accentuating survival in the model of murine melanoma.Animal Model:melanoma tumor model
Dosage:2 mg/kg
Administration:2 mg/kg, iv., the 6th day, once
Result:Significantly increased mice survivability combination with doxorubicin, and relieved mice tumor necrosis phenomena.
体外研究：
LDCA (2-100 μM; 16-72 h) is used in combination with doxorubicin synergistically, enhances the growth inhibition and induces mitochondria-mediated apoptosis by recruiting the caspase cascade, restricting migration, and obviating the clonogenic outgrowth potential of melanoma cells.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备